Skip to main content
. 2024 Dec 5;13:RP97051. doi: 10.7554/eLife.97051

Figure 7. Compound 10 as a novel strategy to overcome trastuzumab resistance.

Figure 7.

(A) Trastuzumab (10 μg/ml, 24 hr)-induced growth inhibitory effects were assessed against parental and TR NCI-N87 cell lines (n=3, mean ± S.D., Student’s t-test, ***p<0.001 vs. parent). (B) Trastuzumab- and compound 10-mediated changes of HER2 and its downstream signaling pathway were evaluated (16 hr treatment at indicated concentrations). (C) Anti-proliferative effects of trastuzumab (10 μg/mL) and compound 10 (10 μM) were evaluated against NCI-N87 TR cell line. Each compound was treated for 10 days (n=3, mean ± S.D., ANOVA, ns = non-significant, *p<0.05 vs. CON). (D) Apoptosis induced by compound 10 in NCI-N87 TR was assessed by FACS analysis with treatment of the compound in a dose-dependent manner (24 hr treatment at indicated concentrations, n=3, mean ± S.D., ANOVA, ns = non-significant, ***p<0.001 vs. CON).

Figure 7—source data 1. Raw unedited gels for Figure 7B.
Figure 7—source data 2. Uncropped and labelled gels for Figure 7B.